Rousselot to unveil gelatin prototypes for medical devices

Rousselot, Darling Ingredients’ premier collagen and gelatin brand, will demonstrate the unique advantages of using gelatin as a high-performance biomaterial for medical devices at COMPAMED 2025, in Düsseldorf. Attendees will have the chance to engage directly with Rousselot’s experts and explore application-driven prototypes – including hemostats, dermal fillers, and microneedles – designed to accelerate formulation development and reduce time to market.

Highlights on display will include gelatin-based films and foams designed for use in hemostatic sponges or anti-adhesion films, offering targeted performance and excellent handling properties for development; flowable hemostats with customizable viscosity, bioresorption, and hemostatic efficiency to meet device requirements; dermal fillers where gelatin enables customized rheology, injectability, and biocompatibility; and microneedle prototypes showcasing gelatin’s ability to help optimize mechanical strength, dissolution rates, and active ingredient delivery.

Gelatin is a trusted biomaterial for developers of advanced medical technologies, valued for its physicochemical properties and proven biocompatibility. Rousselot’s extensive portfolio of modified and non-modified gelatins is known for its high purity, consistent quality, and comprehensive regulatory documentation. These attributes help medical device manufacturers reduce variability in preclinical and clinical development, supporting a fast track to market.